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Immune reactivity towards the bacterial intestinal flora plays an important part in the pathogenesis
of inflammatory bowel disease. Administration of probiotic bacteria has beneficial effects on infectious
and inflammatory diseases, principally in bowel disorders. However, little is known about the
administration of soluble bacterial antigens in intestinal inflammation. We investigated the therapeutic
effects of colifagina in experimental colitis. To assess this effect, C57BL/6 mice with dextran sulphate
sodium-induced colitis were treated with colifagina, or with a placebo, for a period of 10 days. The
mice were monitored, and inflammation was assessed by disease activity index (OAI). Analysis of fecal
IgA concentration and measurement of IgA and inflammatory chemokine production in organ colonic
culture was performed by ELISA. Clinically and histologically, bacterial-lysate-treated mice revealed
significantly fewer OAI and a reduction of colonic histological inflammation. Treatment of healthy
mice with colifagina significantly increased the fecal concentration of IgA and IgA production in organ
culture. Colifagina administration in OSS-treated mice significantly increased the fecal concentration
of IgA and IgA production in organ culture. MIP-l, MIP-2 and RANTES concentrations in colonic
organ culture were significantly lower in colifagina-treated mice than in the placebo group. The use of
colifagina is effective in amelioration of murine colitis.
Inflammatory bowel diseases (IBD), including
Ulcerative Colitis (UC) and Crohn's Disease (CD),
are spontaneously relapsing immunologically
mediated disorders of the gastrointestinal tract.
Although the etiology of IBD remains unknown,
it is commonly believed that disease pathogenesis
is multi-factorial involving genetic, environmental
and immunologic factors. Homeostasis (tolerance)
involves a regulated response of the host to
the constant antigenic drive of enteric bacteria
while chronic intestinal inflammation represents
a malfunction of this tolerance to the comensal
microbiota. In the genetically susceptible host,
the lack of appropriate mechanisms to terminate
mucosal immune responses (loss of immunologic
tolerance) and an ineffective mucosal barrier
function results in continuous stimulation of the
mucosal immune system, excess production of
proinflammatory cytokines and chronic inflammation
as a consequence
Considering the host microbial environment as
the major player in the development ofIBD, recently
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much attention has been placed on the ability to
target the microbiota with the use of probiotics
as an option for therapeutic intervention to help
restore balance to the intestinal microenvironment
and hence reduce the inflammatory response. A
probiotic can be described as "a preparation of or a
product containing viable defined micro-organisms
in sufficient numbers which alter the microflora (by
implantation or colonization) in a compartment of
the host and by that exert beneficial health effects on
this host"(l).
The use of probiotics in the treatment of
inflammatory diseases is not a new concept,
however, their mode of action still remains complex
and not completely understood. Many different
probiotics have been used in the treatment of
several inflammatory conditions including arthritis
(2), pouchitis (3), ulcerative colitis (4-5) Crohn s
disease (6- 7) and experimental colitis (8). Several
mechanisms in which probiotics help improve
intestinal function have been proposed which
include: 1) the prevention of colonization of
pathogenic bacteria to the GI tract by inhibiting their
adhesion via competition; 2) reinforcement of the
epithelial barrier by controlling cellular permeability
(9); 3) alteration of the humoral immune response
by elevating the amount of IgA; 4) regulation
of proinflammatory cytokine production (10).
Interestingly, not all the probiotics used in the IBD
field have proven successful, and each probiotic has
been shown to act in a specific manner.
In this study the therapeutic potential of the
commercially available preparation colifagina
was tested for the first time in IBD. Colifagina
is a preparation of 8 lysed bacteria containing E.
Coli (01, 02, 055 and 0 Ill), Bacillus pumilus,
Morganella morgani, Alcaligens faecalis, Shigella
fexneri, Enterococcus faecalis, Bacillus subtilis
and Proteus vulgaris, which has never been tested
in previous reports. The pathogen strains are
chosen from those most commonly responsible
for gastrointestinal and urogenital infections. The
administration of these pathogens is made possible
by the complete deactivation of these bacteria
through thermal alkaline lysis. Lysed bacteria
maintain the same immunogenic properties as the
corresponding vital bacteria both qualitatively and
quantitatively, with the advantage that the lysed
bacteria do not have the capacity to proliferate
and invade the host thereby causing infection. The
lysed bacteria introduce antigens, which induce
an antibody secretory response via the release of
immunoglobulins, both locally and systemically.
MATERIALS AND METHODS
Animals
Six to eight-week-old male C57BL/6 mice used in this
study, were purchased from Charles River laboratories
(Calco, Italy) and maintained under pathogen-free
conditions in an animal facility at the Instituto Clinico
Humanitas Hospital (Milan, Italy). Experimental
procedures involving animals and their care conformed
with institutional guidelines in compliance with national
and international law after approval by the ethical
committee.
Induction ofcolitis and treatment
The animals were divided into four groups each
containing 10 mice. Two groups received 2.5% (wt/vol)
Dextran sulfate sodium (DSS) (molecular mass, 40 kDa;
MP Biomedicals Irvine, CA), ad libitum in filter-purified
drinking water for ten days, as previously reported (11).
The DSS alone-treated control group received daily
500 III of isotonic sterile saline by oral gavage, while
the treatment group received daily 500 III of colifagina
(ABC FARMACEUTICI, To, Italy) containing bacterial
Iysates; Escherichia coli strain 01, 02, 055, 0111 (6 x
109) , Bacillus Pumilus (4 x 108) , Morganella morgani,
Alcaligenes faecalis, Shigella flexneri, (3 x 108) and
Enterococcus faecalis, Bacillus subtilis, Proteus vulgaris
(8 x 107) by oral gavage. The other two groups consisted
of healthy untreated mice and healthy mice receiving 500
III of colifagina daily.
Determination ofdisease activity
Colitis was scored daily using standard parameters
that include body weight, diarrhea, presence of blood
in the stools, and rectal prolapse. Disease activity index
(DAI) was measured as the combined scores of weight
loss, stool consistency and bleeding divided by 3 (II).
Histological grading ofcolitis
Colonic tissues were fixed in formalin overnight and
embedded in paraffin for histological analysis.
Grading of intestinal inflammation was determined,
as described previously (II), in a blinded fashion by
3 readers: no inflammation (0); modest numbers of
infiltrating cells in the lamina propria (I); infiltration of
mononuclear cells leading to separation of crypts and
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Fig. 1. Colifagina ameliorates clinical DSS colitis Mice weref edfor a period of10 days with colifagina, or placebo. and
monitored daily for disease activi ty index and weight loss. Colifagina significantly (p<0.05) improved disease activity
index. but not weight loss. A and B, *p<0.05 *p<0.05. n=lO per group
A
Placebo Colifagina
B
Fig. 2. Colifagina improves histological inflammation. Mice weref edfor a period of10 days with colifagina, or placebo.
and sacrificed after 10 days. and colons assessedfor histological inflammation (A}. Colifagina treated mice displayed a
significant (*p<O.05) amelioration ofhistological inflammation (B) . *p<0.05, n=10 per group
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ulceration (4), with a histological score from 0 to 15.
Colon organ culture
Colons from all mice were excised, opened and
cut longitudinally in three parts. One of all three parts
was washed in cold PBS supplemented with penicillin,
streptomycin and amphoteracin B (BioWhittaker
Cambrex, Milan) and incubated in serum free RPMI
1640 medium supplemented with 0.1% FBS, penicillin,
streptomycin and amphoteracin B, at 37° in 5% C02. After
24 hours, supernatant fluid was collected, centrifuged and
stored at -20°. Supernatant was analyzed for IL-8, MIP-I,
MIP-2, and RANTES by ELISA as reported (12).
Fecal extracts
Fecal extractswere prepared as follows. Twofecal pellets
were collected from each mouse (housed in separate cages)
weighed and then were mixed with 0.5 ml of extraction
buffer (30 mM disodium EDTA, pH 7.6, 100 ug/ml soybean
trypsin inhibitor, and 10 mglml bovine serum albumin in
PBS). Pellets were homogenized and centrifuged at 4°C, and
supernatants were stored at -20°C until immunoglobulin A
(IgA) measurements were performed.
RESULTS
Statistical analysis
Data were analyzed by Graphpad software (San
Diego, CA) and expressed as mean ± SEM. The Student's
t test or the ANOVA followed by the appropriate post hoc
test were used when appropriate. Statistical significance
was set at p<0.05.
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Fig. 3. Colifagina enhances fecal and colonic secretion of
IgA Mice werefedfor a period of10 days with colifagina,
or placebo, and sacrificed after 10 days, and a colonic
organ culture was established. Total IgA were measured
in the supernatants, as well as in the stools of the mice
at day 10. Colifagina treated mice displayed a higher
IgA content in their stools (p=O.04 for healthy intestine
compared to healthy intestine treated with colifagina, and
p=O.02for DSS versus DSS+colifagina, Fig. 3 A) as well
as in the organ culture (both p=O.03, Fig. 3 B). (n=IO
per group).
mild mucosal hyperplasia (2); massive infiltration with
inflammatory cells accompanied by disrupted mucosal
architecture, loss of goblet cells, and marked mucosal
hyperplasia (3); all of the above plus crypt abscesses or
Colifagina ameliorates clinical and histological
experimental colitis
In our experiments we used mice undergoing
2.5% DSS treatment in drinking water. In our
animal facility, during a period of 10 days, the mice
showed typical signs of disease such as a decrease
in body weight, loose stools and presence of blood
in stools.
To test the capacity of colifagina to ameliorate
experimental colitis, the mice were fed for a
period of 10 days with colifagina or placebo, and
monitored daily for disease activity index and
weight loss. Compared to the placebo group, the
mice treated with colifagina developed less severe
disease resulting in significantly (p< 0.05) improved
disease activity index. Bacterial-lysate-treated
mice revealed significantly fewer signs of colitis
than placebo treated mice, as assessed by a 30%
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Fig. 4. Colifagina inhibits inflammatory chemokine secretion Mice were fed for a period of 10 days with colifagina, or
placebo, and sacrificed after 10 days, and a colonic organ culture was established. Several chemokines were measured
by ELISA. Colifagina treatment significantly inhibited MIP-I (p=O.04), MIP-2 (p=O.04), TNF-a (p=O.03) and RANTES
(p=O.02) secretion (*p<O.05, n=lO per group).
reduction in DAI (p<0.05) (Fig. lA). Surprisingly
colifagina did not have any significant effect on body
weight loss (Fig. IB).
After 10 days of colifagina treatment, the mice
were sacrificed and the colons were assessed for
histological inflammation. Histological examination
of the distal part of the colon of placebo treated
mice showed the typical pathological changes
of colitis, while mice treated concurrently with
colifagina showed significant (p<0.05) amelioration
of histological inflammation (Fig. 2). No colitis
induction was observed in healthy mice treated with
colifagina alone. (Fig. 2).
Colifagina enhancesfecal and colonic secretion ofIgA
After colifagina treatment, the mice were sacrificed
at day 10,intestinesremoved and a colonic organ culture
was established. Total IgA were measured in both the
colonic organ culture supernatants and in the stools of
the mice. Mice treated with 2.5% DSS and colifagina
displayed higher IgA levels both in their stools and in
colonic organ culture compared with mice receiving
placebo and 2.5% DSS (p<0.05, Fig. 3A and B). In
addition, healthy mice receiving colifagina showed a
significant (p<0.05) increase in the production of IgA
in both stools and colon organ culture with respect to
untreated healthy mice (Fig. 3A and B).
Colifagina inhibits inflammatory chemokine
secretion
In the same organ culture, besides IgA production,
inflammatory cytokine and chemokine levels were
also measured by Elisa.
In healthy, untreated mice little to no production
of TNF-a, MIP-l, MIP-2 and RANTES was
detected, comparable to healthy mice receiving
colifagina (Fig. 4). As expected, expression levels
of the pro-inflammatory mediators significantly
increased in DSS treated mice with respect to
healthy mice. Interestingly, DSS colitic mice treated
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with colifagina displayed a significant inhibition
(p<0.05) of TNF-a, MIP-l, MIP-2, and RANTES
secretion.
DISCUSSION
Previous studies have demonstrated that
probiotics have inhibitory effects on pathogenic
bacteria of the gastro-intestinal tract. Several
mechanisms by which probiotics enhance protection
against pathogens have been suggested, including
prevention of colonization of pathogenic bacteria
to the GI tract by inhibiting their adhesion via
competition, reinforcement of the epithelial barrier
by controlling cellular permeability, alteration of the
humoral immune response, and regulation of pro-
inflammatory cytokine production.
Our data suggests that treatment with the
probiotic colifagina may effectively improve clinical
experimental colitis. The protection obtained by
the use of colifagina correlates well with enhanced
mucosal immune responses evidenced by an increase
in both fecal and colonic IgA secretion and a relevant
decrease in the expression of pro-inflammatory
cytokine and chemokines such as TNF-a, MIP-l,
MIP-2, and RANTES.
One finding of our study was that administration
of colifagina significantly altered the severity of
clinical and histological colitis, even though it had
no effect on percentage body weight loss.
Notably, colifagina induced a strong production
of both fecal and colonic IgA, both in healthy and
colitic mice, acting as an enterovaccine. These
observations are in line with previous studies that
show a significant increase in intestinal antibacterial
IgA levels in probiotic fed mice (13-14). Our
results therefore strongly suggest that one of the
mechanisms through which the probiotic colifagina
ameliorates colitis is by improving the intestine's
immunological barrier and by enhancing local
IgA production. Secretory IgA released from the
intestinal mucosal surface is resistant to proteolysis
and does not activate complement or inflammatory
responses (15). For this very reason, IgAhas a central
role in the mucosal immune system by preventing
the adherence of pathogenic enteric bacteria to the
epithelial cells and neutralizing biologically active
antigens like bacterial toxins or viruses (16-17). In
humans, Lactobacillus GG bacteria, (LGG) have
been reported to promote IgA production in children
affected by CD. In adult CD patients oral application
of L. Casei strain for 10 days led to a significant
increase in mucosal IgA levels. The results from this
study suggest an improvement of the immunological
barrier (18).
In our study we also observed that colifagina
administration has the capacity to inhibit the pro-
inflammatory cytokines and chemokines TNF-a,
MIP-l, MIP-2 and RANTES, thus displaying anti-
inflammatory effects. Similarly, other probiotics such
as Lactobacillus GG Bacteria (LGG) have been largely
used in clinical trials and experimental models and
have been shown to be able to alter the expression of
several pro-inflammatory cytokines including TNF-a.
(19) interleukins IL-l beta, IL-8 and IFN-y (8, 20).
Taken together, our results suggest that colifagina
may have a therapeutic role in ameliorating intestinal
inflammation by enhancing gut immune defense by
stimulating IgA production, and by down-regulating
the secretion of several pro-inflammatory cytokines.
In conclusion, our results suggest that lysed bacteria
like colifagina may serve as a promising new
therapeutic option for the treatment of IBD, but
before this data can be translated into clinical trials
the findings need to be confirmed by independent
groups and other experimental models of colitis,
such as the TNBS model, and controlled clinical
trials in human patients are also necessary.
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